Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus.
Publication/Presentation Date
12-1-2018
Abstract
A full-term newborn with kaposiform hemangioendothelioma (KHE) affecting the right thigh with thrombocytopenia due to Kasabach-Merritt phenomenon (KMP) was referred to our center. After biopsy, he rapidly evolved to severe thrombocytopenia and severe coagulopathy. Standard therapy was initiated with prednisolone and vincristine. His coagulopathy worsened to life-threatening hemorrhage necessitating aggressive blood products replacement. Sirolimus was added; he became transfusion independent with no further bleeding and reduction in tumor size. Addition of sirolimus to treatment of vascular anomalies with hemostatic complications should be considered as part of early treatment for patients with KMP/KHE.
Volume
65
Issue
12
First Page
27305
Last Page
27305
ISSN
1545-5017
Published In/Presented At
Cashell, J., Smink, G. M., Helm, K., & Xavier, F. (2018). Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus. Pediatric blood & cancer, 65(12), e27305. https://doi.org/10.1002/pbc.27305
Disciplines
Medicine and Health Sciences | Pediatrics
PubMedID
30070028
Department(s)
Department of Pediatrics
Document Type
Article